Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Spain; University of Alcalá, Madrid, Spain.
Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Spain.
Hipertens Riesgo Vasc. 2023 Oct-Dec;40(4):215-221. doi: 10.1016/j.hipert.2023.08.001. Epub 2023 Nov 22.
Primary aldosteronism (PA) is the most common cause of secondary arterial hypertension. For unilateral cases, surgery offers the possibility of cure, with unilateral adrenalectomy being the treatment of choice, whereas bilateral forms of PA are treated mainly with mineralocorticoid receptor antagonists (MRA). The goals of treatment for PA due to either unilateral or bilateral adrenal disease include reversal of the adverse cardiovascular effects of hyperaldosteronism, normalization of serum potassium in patients with hypokalemia, and normalization of blood pressure. The Primary Aldosteronism Surgery Outcome group (PASO) published a study defining clinical and biochemical outcomes based on blood pressure and correction of hypokalemia and aldosterone to renin ratio (ARR) levels for patients undergoing total unilateral adrenalectomy for unilateral PA. In this review, we provide several practical recommendations for the medical and surgical management and follow-up of patients with PA.
原发性醛固酮增多症(PA)是继发性高血压的最常见病因。对于单侧病例,手术提供了治愈的可能,单侧肾上腺切除术是首选治疗方法,而双侧 PA 主要采用盐皮质激素受体拮抗剂(MRA)治疗。单侧或双侧肾上腺疾病引起的 PA 的治疗目标包括逆转醛固酮增多症的不良心血管影响、纠正低钾血症患者的血清钾水平以及使血压正常化。原发性醛固酮增多症手术结果组(PASO)发表了一项研究,该研究根据血压以及低钾血症和醛固酮与肾素比值(ARR)水平的纠正,为单侧 PA 行单侧肾上腺全切除术的患者定义了临床和生化结局。在这篇综述中,我们为 PA 患者的医疗和手术管理及随访提供了一些实用建议。